Predisposition Biomarkers: Technologies and Global Markets

October 2019 | 72 pages | ID: PB8E0FC5B692EN
BCC Research

Abstracts

REPORT INCLUDES:

• An overview of technologies and global markets for the predisposition biomarkers
• Analyses of the global market trends with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
• Information on recent key technical advances in different predisposition biomarkers, as well as the extent of adoption by commercial customers and regulatory authorities
• Identification of key areas of growth and the key strategies of major players in the market
• A look at recent diagnostic test developments and revelations as well as knowledge of how they will influence selected clinical markets

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Market Definition
Key Takeaways
Key Recommendations

CHAPTER 4 MARKET BREAKDOWN BY END USER

Hospitals
Research Institutes

CHAPTER 5 MARKET BREAKDOWN BY APPLICATION

Cancer
Neurological Diseases
Cardiovascular Diseases
Diabetes
Other Diseases

CHAPTER 6 MARKET BREAKDOWN BY REGION

North America
United States
Canada
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of World

CHAPTER 7 PATENT REVIEW AND NEW DEVELOPMENTS

Recent Developments

CHAPTER 8 COMPETITIVE LANDSCAPE

BioMerieux Inc.
Recent Developments
F. Hoffmann-La Roche Ltd.
Recent Developments
Merck KGaA
Recent Developments
QIAGEN N.V.
Recent Developments
Thermo Fisher Scientific Inc.
Recent Developments
Myriad Genetics Inc.
Recent Developments

CHAPTER 9 COMPANY PROFILES

ABCODIA LTD.
ADMERA HEALTH
ADX NEUROSCIENCES NV
AMPRION INC.
BIO-RAD LABORATORIES INC.
COMPUGEN LTD.
EPIGENOMICS AG
MIRNAXBIOSENS, S.L
ONCIMMUNE LTD.
OPTOS PLC

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Predisposition Biomarkers, by Application, Through 2024
Table 1: Global Market for Predisposition Biomarkers, by End User, Through 2024
Table 2: Global Market for the Application of Predisposition Biomarkers in Hospitals, by Region, Through 2024
Table 3: Global Market for the Application of Predisposition Biomarkers in Research Institutes by Region, Through 2024
Table 4: Research Institutes Working on Cancer Studies Across the Globe
Table 5: Global Market for Predisposition Biomarkers, by Application, Through 2024
Table 6: Clinically Relevant Biomarkers for Lung Cancer
Table 7: Global Market for Cancer Predisposition Biomarkers, by Region, Through 2024
Table 8: Global Incidence and Prevalence of Common Neurological Diseases, 2017
Table 9: Global Market for Neurological Predisposition Biomarkers, by Region, Through 2024
Table 10: List of Biomarkers Associated with CVDs
Table 11: Global Market for Predisposition Biomarkers for CVDs, by Region, Through 2024
Table 12: Global Market for Diabetes Predisposition Biomarkers, by Region, Through 2024
Table 13: Characteristics of Biomarkers for Prediabetes, Diabetes and Associated Complications
Table 14: Global Market for Other Applications of Predisposition Biomarkers, by Region, Through 2024
Table 15: Global Market for Predisposition Biomarkers, by Region, Through 2024
Table 16: North American Market for Predisposition Biomarkers, by Country, Through 2024
Table 17: North American Market for Predisposition Biomarkers, by End User, Through 2024
Table 18: North American Market for Predisposition Biomarkers, by Application, Through 2024
Table 19: Active Early Detection Research Network Grants in the U.S., 2019
Table 20: Funding for Research on Biomarkers for Alzheimer’s in Canada
Table 21: European Market for Predisposition Biomarkers, by Country, Through 2024
Table 22: European Market for Predisposition Biomarkers, by End User, Through 2024
Table 23: European Market for Predisposition Biomarkers, by Application, Through 2024
Table 24: Cancer Incidences and Mortalities in Europe, 2018
Table 25: Major Neurological Incidences in Europe in 2017
Table 26: Asia-Pacific Market for Predisposition Biomarkers, by Country, Through 2024
Table 27: Asia-Pacific Market for Predisposition Biomarkers, by Application, Through 2024
Table 28: Asia-Pacific Market for Predisposition Biomarkers, by End User, Through 2024
Table 29: Cancer Incidence and Mortalities in Asia-Pacific, 2018
Table 30: Active Dementia Research Grants in Australia
Table 31: Rest of the World Market for Predisposition Biomarkers, by Application, Through 2024
Table 32: Rest of the World Market for Predisposition Biomarkers, by End User, Through 2024
Table 33: Number of Patents, by Country, January 2015-May 2019
Table 34: Number of Patents, by Company/Organization
Table 35: Number of Patents Registered, by Year
Table 36: BioMerieux Inc.: Financial Analysis, 2017 and 2018
Table 37: F. Hoffmann-La Roche Ltd.: Financial Analysis, 2017 and 2018
Table 38: Merck KGaA: Financial Analysis, 2017 and 2018
Table 39: QIAGEN N.V.: Financial Analysis, 2017 and 2018
Table 40: Thermo Fisher Scientific Inc.: Financial Analysis, 2017 and 2018
Table 41: Myriad Genetics Inc.: Financial Analysis, 2017 and 2018

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Predisposition Biomarkers, by Application, 2018-2024
Figure 1: Global New Cancer Cases, by Type, 2018
Figure 2: Prevalence of Cancer, by Type, 2018
Figure 3: BioMerieux Inc.: Revenue, by Region, 2018
Figure 4: F. Hoffmann-La Roche Ltd.: Revenue, by Operating Segment, 2018
Figure 5: Merck KGaA: Revenue, by Region, 2018
Figure 6: QIAGEN N.V.: Revenue, by Region, 2018
Figure 7: Thermo Fisher Scientific Inc.: Revenue, by Region, 2018
Figure 8: Myriad Genetics Inc.: Revenue, by Operating Segment, 2018